GEIST:UPC Searchengine

UPC_CFI_1/2023

Amgen, Inc. v. Sanofi-Aventis Deutschland GmbH

Datum
2023-09-20
Kammer
Munich (DE) Central Division - Section
Verfahrensart
Revocation Action
Sprache
EN

Metadaten

Fall-IDUPC_CFI_1-2023-0c7d0a204eb3
Aktenzeichen
RegisterzeichenUPC_CFI_1/2023
EntscheidungsreferenzORD_550152/2023
Schlagwörter
Leitsätze

Dokumente und Volltext

Textextraktion: pypdf | Seiten: 8

1 Central Division (Section Munich) UPC_CFI_1/2023 Order rejecting Rule 262.1(b) RoP request of the Court of First Instance of the Unified Patent Court delivered on 20/09/2023 HEADNOTES: Rule 262.1(b) RoP requires a concrete and verifiable, legitimate reason for making available written pleadings and evidence upon a request by a member of the public. The wish from a natural person to form an opinion on the validity of a patent out of a personal and a professional interest is not a legitimate reason as required by Rule 262.1(b) RoP. Keywords: Rule 262.1(b) RoP request (rejected). Legitimate reason for access (no). REFERENCE CODE ECLI: Not provided APPLICANT/S 1) … (Applicant) - … - … Represented by … … RESPONDENT/S 2 RELEVANT PROCEEDING PARTIES 1) Sanofi-Aventis Deutschland GmbH (Claimant)  ...